Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc., the clinical-stage life sciences company, said it has appointed Teri Loxam and its chief financial officer Chris Waddick to serve as board directors, effective immediately.
Loxam has over 25 years of experience in the pharmaceutical, life sciences, and entertainment industries, while Waddick has over 30 years of experience in financial and executive roles in the biotechnology and energy industries, the company said.
"We are delighted that Teri and Chris have agreed to join our board of directors," Dr Guillermo Torre, chairman of Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said in a statement. "Their extensive and diversified experience will be invaluable to our continued growth and success as we advance the development of important new anti-fibrotic and anti-inflammatory therapeutics for the treatment of heart disease."
READ: Cardiol Therapeutics receives US FDA authorization for Phase II study of CardiolRx for recurrent pericarditis
Loxam has held various roles spanning strategy, investor relations, finance, and communications. Most recently, she joined Kira Pharmaceuticals in November 2021 as chief operating officer (COO) and CFO. In this role, she oversees finance, operations, and strategic functions for the company.
Prior to Kira, Loxam served as CFO at SQZ Biotech, where she helped take the company public via an IPO on NYSE, as senior vice president of investor relations and global communications at Merck, and as vice president, investor relations for IMAX Corporation.
She holds an MBA from the University of California, Irvine, and a Bachelor of Science (BSc) degree in Biology from the University of Victoria, B.C. Canada.
Waddick has “substantial knowledge” of public company management and corporate governance, and in designing, building, and managing financial processes, procedures, and infrastructure, Cardiol noted.
In addition to his role as CFO and corporate secretary of Cardiol, which he has held since August 16, 2018, Waddick serves as executive vice president and CFO for a private Ontario energy company.
Previously, he spent more than 12 years at biotech company Vasogen (TSX:VAS) Inc., serving as CFO and COO while the company grew from start-up to an organization employing over 250 employees that established the necessary systems and infrastructure to advance an anti-inflammatory therapy through to the completion of an international multi-center pivotal trial involving 2,500 patients.
Waddick is a chartered professional accountant (CPA) and earned a business degree from Wilfrid Laurier University and a Master of Business Administration from York University.
Oakville, Ontario-based Cardiol is a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-fibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease.
Contact the author at jon.hopkins@proactiveinvestors.com